Paratek’s Seysara (sarecycline) Receives FDA’s Approval for Treatment of Moderate to Severe Acne

 Paratek’s Seysara (sarecycline) Receives FDA’s Approval for Treatment of Moderate to Severe Acne

Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and OASIS-1 Studies for Pneumonia and Skin Infections in Adults, Published in NEJM

Shots:

  • The approval is based on P-III study results assessing Seysar (sarecycline) in patients with inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older
  • The study resulted in safe and effective results in P-III study in patients with moderate to server acne
  • Seysara (sarecycline) is a qd, PO, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne

Click here to read full press release/ article | Ref: Paratek | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post